Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gains from Sales and Divestitures (2016 - 2017)

Ultragenyx Pharmaceutical has reported Gains from Sales and Divestitures over the past 3 years, most recently at $156021.0 for Q4 2017.

  • Quarterly Gains from Sales and Divestitures rose 198.47% to $156021.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $156021.0 through Dec 2017, up 198.47% year-over-year, with the annual reading at $156021.0 for FY2017, 198.47% up from the prior year.
  • Gains from Sales and Divestitures was $156021.0 for Q4 2017 at Ultragenyx Pharmaceutical, up from $52273.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $156021.0 in Q4 2017 and troughed at $18209.0 in Q4 2015.
  • The 3-year median for Gains from Sales and Divestitures is $52273.0 (2016), against an average of $75501.0.
  • Year-over-year, Gains from Sales and Divestitures skyrocketed 187.07% in 2016 and then skyrocketed 198.47% in 2017.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $18209.0 in 2015, then soared by 187.07% to $52273.0 in 2016, then soared by 198.47% to $156021.0 in 2017.
  • Per Business Quant, the three most recent readings for RARE's Gains from Sales and Divestitures are $156021.0 (Q4 2017), $52273.0 (Q4 2016), and $18209.0 (Q4 2015).